Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit – Markets Insider
|
Poseida Therapeutics Presents Novel BCMA-Specific CAR–T Therapy at CAR-TCR Summit
Markets Insider SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving cell therapies, today presented preclinical data on P-BCMA-101, the … |
